"10.1371_journal.pone.0106631","plos one","2014-09-19T00:00:00Z","Dov Shiffman; Guillaume Pare; Rainer Oberbauer; Judy Z Louie; Charles M Rowland; James J Devlin; Johannes F Mann; Matthew J McQueen","Celera, Alameda, CA, United States of America; Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada; Department of Nephrology, KH Elisabethinen, Linz, Austria and Department of Nephrology, Medical University of Vienna, Vienna, Austria; Department of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Germany","Conceived and designed the experiments: DS GP RO JJD JFM MJM. Performed the experiments: GP DS MJM. Analyzed the data: DS GP JJD JZL CMR. Contributed reagents/materials/analysis tools: GP JFM MJM. Wrote the paper: DS GP RO JJD JFM MJM.","DS, JZL, CMR, and JJD are employees of Celera, a Quest Diagnostics company. DS, GP, JZL, CMR, JJD and MJM are named as inventors on the following patent application filed by Quest Diagnostics relating to the association of CERS2 variants with increased albuminuria “GENETIC POLYMORPHISMS ASSOCIATED WITH CHRONIC KIDNEY DISEASE, METHODS OF DETECTION AND USES THEREOF” Provisional applications serial no. 61/836,403 and serial no. 61/836,491). Boehringer Ingelheim has funded the ONTARGET and TRANSCEND studies. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2014","09","Dov Shiffman","DS",8,TRUE,6,3,5,6,TRUE,TRUE,FALSE,0,NA,FALSE
